April 29, 2026

SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

Cambridge, UK, and Heidelberg, Germany, 13 April 2026: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and the European Molecular Biology Laboratory’s Genomics Core Facility (EMBL GeneCore), today announced a collaboration to advance fully walkaway automated genomics workflows. As part of the collaboration, SPT Labtech’s firefly®+ all-in-one liquid handling platform has been installed at EMBL GeneCore, an internationally recognized, state-of-the-art genomics service center. 

Through the installation of firefly+, EMBL GeneCore will expand its capacity to develop new protocols and further validate and optimize existing workflows for challenging applications such as low-input and metagenomics samples to support the broader genomics community. SPT Labtech’s firefly+ all-in-one liquid handling platform is a compact and highly flexible automation solution designed to simplify complex genomics workflows, combining pipetting, dispensing, incubating, and shaking technologies into a single instrument.

The automated protocols use New England Biolabs® (NEB) library preparation kits, NEBNext®, to generate high-yield, high-quality libraries from a wide input range. Designed for simplicity and efficiency, the kits enable development of low bias, high-sensitivity NGS protocols, with minimal plastic waste.

Installation of SPT Labtech’s firefly+ platform at EMBL GeneCore, combined with the simplicity of NEB® kits, creates a robust foundation for fully walkaway automation, enabling more streamlined, end-to-end workflows and supporting labs to scale automation more easily.

Vladimir Benes, Head of Genomics Core Facility (GeneCore) at EMBL, said: “The installation of SPT Labtech’s firefly+ platform as part of our collaboration underscores our commitment to remain at the forefront of scientific innovation. Fully walkaway automation will address key bottlenecks in genomics workflows, helping us develop  high-quality, scalable NGS protocols.”

Morten Frost, Chief Commercial Officer, SPT Labtech, commented: “Our latest collaboration with EMBL GeneCore marks a significant step towards advancing fully walkaway automation, providing end-to-end genomics workflows for a much wider range of applications, including environmental and rare species research. We are excited to expand access to our firefly+ platform in Europe through collaboration in the biotech hub of Heidelberg, where strong industry collaborations are driving ecosystem growth.”

Bjoern Textor PhD, Sales and Senior Applications Manager, New England Biolabs GmbH, added: “Integration of our library prep kits with SPT Labtech’s firefly+ platform at EMBL GeneCore creates a compelling opportunity for faster, scalable DNA and RNA-Seq workflows, and we look forward to working together to develop novel solutions to overcome persistent challenges in genomics research.”

Our latest News

discover more
SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

Cambridge, UK, and Heidelberg, Germany, 13 April 2026: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and the European Molecular Biology Laboratory’s Genomics Core Facility (EMBL GeneCore), today announced a collaboration to advance fully walkaway automated genomics workflows. As part of the collaboration, SPT Labtech’s firefly®+ […]

AskBio’s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

AskBio’s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency Berlin, Germany, and Durham, N.C., USA, April 20, 2026 – AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it has introduced its proprietary, commercially ready […]

Molecular signature linked to aggressive growth of head and neck tumors discovered

Molecular signature linked to aggressive growth of head and neck tumors discovered

Researchers from Heidelberg University’s Faculty of Medicine and the Technical University of Munich have investigated the genetic activity of “budding” head and neck carcinomas. In the “buds”—clusters of cells that detach from the tumor and are associated with a poor prognosis—they found a characteristic pattern of gene activity. This marker signature provides insights into the […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp